uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
HER-2 overexpression (3+) in patients with squamous cell carcinoma correlates with poorer survival
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Oncology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Genetics and Pathology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Oncology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Oncology.
Show others and affiliations
2006 (English)In: Diseases of the esophagus, ISSN 1120-8694, E-ISSN 1442-2050, Vol. 19, no 4, 224-231 p.Article in journal (Refereed) Published
Abstract [en]

The incidence of esophageal carcinoma is increasing worldwide. In Sweden, approximately 400 patients are diagnosed each year. The present study retrospectively investigates survival in 97 patients with esophageal carcinoma in regard to their HER-2 status as examined by immunohistochemistry (IHC) and chromogen in situ hybridization (CISH). Sixty-eight patients had localised disease and 29 patients had advanced disease. Seventy patients had squamous cell carcinoma, and nine of these patients (13%) had HER-2 overexpression (3+). Eight (30%) of 27 adenocarcinoma patients overexpressed (3+) HER-2. In patients overexpressing (3+) HER-2 a statistical trend towards poorer survival was observed (P = 0.057). In squamous cell carcinoma patients, HER-2 overexpression (3+) correlated with poorer survival (P = 0.035), whereas in adenocarcinoma patients, HER-2 status (3+) did not. HER-2 amplification according to CISH was present in five (two squamous cell carcinomas and three adenocarcinomas) out of 17 HER-2 overexpressing (3+) tumours. In conclusion, HER-2 overexpression (3+) seems to be associated with poorer survival in esophageal carcinomas, especially in patients with squamous cell esophageal carcinoma.

Place, publisher, year, edition, pages
2006. Vol. 19, no 4, 224-231 p.
Keyword [en]
Adenocarcinoma/genetics/metabolism/mortality/therapy, Aged, Esophageal Neoplasms/genetics/*metabolism/*mortality/therapy, Female, Gene Expression, Genes; erbB-2, Humans, Immunohistochemistry, In Situ Hybridization, Male, Neoplasm Metastasis, Neoplasms; Squamous Cell/genetics/*metabolism/*mortality/therapy, Radiation Tolerance, Receptor; erbB-2/*metabolism, Retrospective Studies, Survival Analysis
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-94406DOI: 10.1111/j.1442-2050.2006.00570.xPubMedID: 16866851OAI: oai:DiVA.org:uu-94406DiVA: diva2:168243
Available from: 2006-04-28 Created: 2006-04-28 Last updated: 2017-12-14Bibliographically approved
In thesis
1. Predictive Factors in Esophageal Carcinoma
Open this publication in new window or tab >>Predictive Factors in Esophageal Carcinoma
2006 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Esophageal carcinoma is a malignancy with a poor prognosis and is the sixth cause of cancer related death worldwide. In Sweden approximately 400 new cases are diagnosed every year. The aim of this present thesis was to investigate predictive factors for esophageal carcinoma patients.126 esophageal carcinoma patients admitted to the department of Oncology at the University Hospital in Uppsala between 1990-2000 were investigated with focus on known and potential prognostic factors. Performance status and stage of the disease were the only independent prognostic factors (p-values <0.001).

Angiogenic factors VEGF and bFGF were correlated to platelet and leukocyte counts and VEGF was correlated to tumor volume (p=0.04) whereas bFGF was not (p=0.08) in pre-treatment serum samples from 42 esophageal carcinoma patients. The use of the angiogenic factors as prognostic factors, prior to therapy in patients with esophageal carcinoma, according to the results from the present study, seems limited.

HER-2 overexpression was seen in 17% of 97 investigated esophageal tumor samples. In squamous cell carcinoma patients, HER-2 overexpression correlated with poorer survival (p=0.035), whereas in adenocarcinoma patients, HER-2 status did not. HER-2 overexpression seems to be associated with poorer survival in esophageal carcinomas, especially in patients with squamous cell esophageal carcinoma.

Telomerase activity was detected in all esophageal cell lines, with a broad range of activity levels. No correlation was found between telomerase activity levels and sensitivity to investigated cytotoxic drugs. We therefore conclude that basal telomerase activity level is not a key determinant of sensitivity to standard cytotoxic drugs in esophageal carcinoma cell lines.

The virus HPV-16 was detected in 16 % of the patients; no other type HPV was detected. HPV-16 infection had no significant effect on survival (p=0.72). Our results did not show that HPV-16 increases survival or improve therapy response in patients with esophageal carcinoma.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2006. 85 p.
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 147
Keyword
Oncology, Esophageal carcinoma, Survival, Prognosis, Angiogenesis, HER-2, Telomerase, FMCA, HPV, Onkologi
Identifiers
urn:nbn:se:uu:diva-6831 (URN)91-554-6550-1 (ISBN)
Public defence
2006-05-20, Skoogsalen, Akademiska sjukhuset, Ingång 78, Uppsala, 09:15
Opponent
Supervisors
Available from: 2006-04-28 Created: 2006-04-28 Last updated: 2011-02-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Wanders, AlkwinWagenius, GunnarBergqvist, Michael

Search in DiVA

By author/editor
Wanders, AlkwinWagenius, GunnarBergqvist, Michael
By organisation
OncologyDepartment of Genetics and Pathology
In the same journal
Diseases of the esophagus
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 513 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf